Effect of garlic powder on C-reactive protein and plasma lipids in overweight and smoking subjects
article
Background: Epidemiologic studies suggest that garlic may have beneficial effects on risk factors associated with cardiovascular disease (CVD). However, these findings are not unambiguously supported by randomized placebo-controlled clinical trials. Objective: We sought to investigate the effects of a chemically well-characterized garlic preparation on biomarkers for inflammation, endothelial function, and lipid metabolism in subjects with risk factors for CVD. Design: This was a double-blind, randomized, placebo-controlled trial in 90 overweight [body mass index (in kg/m2) > 24.5] subjects aged 40-75 y who smoked >10 cigarettes/d. The subjects were randomly assigned to 3 parallel treatment groups: garlic powder (2.1 g/d), atorvastatin (40 mg/d), or placebo. Duplicate measurements were performed at baseline and after 1 and 3 mo of treatment. Treatments were compared with analysis of covariance with baseline as the covariate, and differences between the treatments were reported as mean percentage difference and corresponding 97.5% CI. Results: None of the variables showed significant differences between the garlic-treated and the placebo groups. In contrast, compared with the placebo group, atorvastatin treatment resulted in significantly lower plasma concentrations of C-reactive protein (20.2%; 1.7%, 35.3%), total cholesterol (37.2%; 33.1%, 41.1%), LDL cholesterol (52.7%; 47.9%, 57.1%), triacylglycerols (31.9%; 20.8%, 41.5%), and tumor necrosis factor α (TNF-α; 41.9%; 19.0%, 58.3%) and increased the ratio of ex vivo whole blood lipopolysaccharide-stimulated to nonstimulated TNF-α concentrations (109.7%; 37.9%, 218.9%). Conclusion: We conclude that a chemically well-characterized garlic preparation has no significant effect on inflammatory biomarkers, endothelial function, or lipid profile in normolipidemic subjects with risk factors for CVD. © 2006 American Society for Nutrition. Chemicals / CAS: atorvastatin, 134523-00-5, 134523-03-8; C reactive protein, 9007-41-4; Anticholesteremic Agents; atorvastatin, 110862-48-1; Biological Markers; C-Reactive Protein, 9007-41-4; Cholesterol, 57-88-5; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Lipids; Plant Extracts; Powders; Pyrroles; Triglycerides
Topics
Biomedical ResearchCRPEndothelial functionatorvastatinbiological markerC reactive proteingarlic extractlow density lipoprotein cholesterolplaceboprintanortriacylglyceroltumor necrosis factor alphaabdominal discomfortcardiovascular diseasecardiovascular riskcell functioncholesterol blood levelclinical trialcontrolled clinical trialcontrolled studydouble blind proceduredrug effectinflammationlipid blood levellipid metabolismmajor clinical studyobesitypatient complianceprotein blood levelrandomized controlled trialside effectsmokingtriacylglycerol blood levelunspecified side effectAdultAgedAnalysis of VarianceAnticholesteremic AgentsBiological MarkersC-Reactive ProteinCholesterolCholesterol, HDLCholesterol, LDLDouble-Blind MethodEndotheliumFemaleGarlicHeptanoic AcidsHumansLipidsMaleMiddle AgedOverweightPlant ExtractsPowdersPyrrolesSmokingTriglyceridesAllium sativum
TNO Identifier
239745
ISSN
00029165
Source
American Journal of Clinical Nutrition, 84(6), pp. 1324-1329.
Pages
1324-1329
Files
To receive the publication files, please send an e-mail request to TNO Repository.